Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478933 | 0.83 | HDAC1 (0.61) | PRKCICREBBPMAPTCES2CES1 | |
| SCHEMBL29388181 | 0.83 | HDAC1 (0.61) | PRKCICREBBPMAPTCES2CES1 | |
| SCHEMBL8013848 | 0.83 | GAA (0.52) | MAPTTDP1CES2CES1HDAC1 | |
| SCHEMBL15709407 | 0.81 | GAA (0.41) | PRKCICREBBPMAPTTDP1CES2 | |
| SCHEMBL15709409 | 0.81 | GAA (0.41) | PRKCICREBBPMAPTTDP1CES2 | |
| SCHEMBL15709405 | 0.81 | GAA (0.41) | PRKCICREBBPMAPTTDP1CES2 | |
| SCHEMBL3078849 | 0.81 | PARP1 (0.50) | MAPTTDP1CES2CES1HDAC1 | |
| Hydrochloric Acid SCHEMBL8752684 | 0.81 | GAA (0.50) | MAPTTDP1CES2CES1HDAC1 | |
| SCHEMBL8752661 | 0.81 | MAPT (0.50) | MAPTTDP1CES2CES1HDAC1 | |
| SCHEMBL29475726 | 0.81 | KDM4E (0.58) | MAPTTDP1CES2CES1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0705100-A4 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-05-29 | — | — | EP | disclosed |
| EP-0705100-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1994027591-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-4929272-A | N-phenyl-maleimides and N-phenyl-succinimides and their use in a herbicidal and/or plant growth regulating action | CIBA-GEIGY CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| US-4804400-A | PRE- AND POSTEMERGENCE; GRAINS | CIBA-GEIGY CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0260228-A2 | N-phenyl-malein imides and N-phenyl-succinimides with a herbicidal and a plant growth regulation activity | CIBA-GEIGY AG (CH) | 1988-03-16 | — | — | EP | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | PRKCI 1185/4885CREBBP 65/4885MAPT 1731/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | PRKCI 1185/4885CREBBP 65/4885MAPT 1731/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | PRKCI 383/4885CREBBP 2015/4885MAPT 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.